WESPAC Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$453K Sell
492
-40
-8% -$40.6K 0.25% 113
2025
Q4
$572K Sell
532
-44
-8% -$42.1K 0.31% 97
2025
Q3
$439K Hold
576
0.26% 123
2025
Q2
$449K Hold
576
0.31% 114
2025
Q1
$476K Sell
576
-198
-26% -$165K 0.39% 97
2024
Q4
$598K Sell
774
-1,685
-69% -$1.4M 0.44% 88
2024
Q3
$2.18M Buy
2,459
+84
+4% +$75.5K 1.61% 8
2024
Q2
$2.15M Sell
2,375
-484
-17% -$387K 1.68% 10
2024
Q1
$2.22M Buy
2,859
+322
+13% +$229K 1.3% 15
2023
Q4
$1.48M Buy
2,537
+353
+16% +$206K 1.03% 23
2023
Q3
$1.17M Buy
2,184
+397
+22% +$205K 0.88% 37
2023
Q2
$838K Hold
1,787
0.67% 52
2023
Q1
$614K Sell
1,787
-972
-35% -$328K 0.58% 56
2022
Q4
$1.01M Buy
2,759
+100
+4% +$35.5K 1.75% 15
2022
Q3
$860K Buy
+2,659
New +$842K 1.16% 30
2021
Q2
Sell
-1,300
Closed -$243K 131
2021
Q1
$243K Buy
+1,300
New +$254K 0.18% 141
2019
Q2
Sell
-19,935
Closed -$2.59M 132
2019
Q1
$2.59M Buy
+19,935
New +$2.42M 1.79% 22

Other funds holding LLY

WESPAC Advisors's LLY Position: Q1 2026 in Review

WESPAC Advisors reduced its Eli Lilly (LLY) stake by 7.5% in Q1 2026, selling an estimated $40.6K and leaving 492 shares worth $453K. The position accounts for 0.25% of the portfolio, ranked #113.

WESPAC Advisors first reported a position in LLY in Q1 2019 and has held it in 17 quarters since. The position peaked at $2.59M in Q1 2019. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • WESPAC Advisors held 492 shares of Eli Lilly worth $453K as of Q1 2026.
  • WESPAC Advisors sold 40 Eli Lilly shares in Q1 2026, an estimated $40.6K.
  • Eli Lilly made up 0.25% of WESPAC Advisors's portfolio in Q1 2026, its #113 holding.
  • WESPAC Advisors first reported a position in Eli Lilly in Q1 2019 and has held it in 17 quarters since.
  • WESPAC Advisors's Eli Lilly position peaked at $2.59M in Q1 2019.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on WESPAC Advisors's 13F filing for Q1 2026, filed 29 Apr 2026.